摘要
目的探讨Beclin-1蛋白表达对转移性肺癌抗血管生成因子治疗敏感性的影响。方法收集2017年1月~2018年1月收治的非小细胞肺癌伴血行转移患者80例,依据病理组织Beclin-1表达分为阴性组和阳性组,给予培美曲塞联合顺铂+Bevacizumab治疗,比较两组患者临床疗效,并测定患者血管内皮生长因子(VEGF),Bcl-2在肺组织中的表达水平,采用多因素分析方法分析患者预后。结果阳性组患者临床治疗有效率显著低于阴性组(P<0.01)。阳性组患者肺组织中各指示物表达水平与阴性组比较差异无统计学意义(P>0.05),但血清CECs水平显著高于阴性组(P<0.05)。COX回归分析显示吸烟,Beclin-1阳性、CECs和CEPCs高表达是影响预后的独立因素。结论 Beclin-1蛋白高表达会影响转移性肺癌抗血管生成因子治疗敏感性从而恶化患者病情。
Objective To investigate the relationship between the expression of Beclin-1 protein and the sensitivityof anti-angiogenic factor therapy in metastatic lung cancer.MethodsEighty patients with non-small cell lung cancer withhematogenous metastasis were collected from January 2017 to January 2018. According to the expression of Beclin-1 in patho-logical tissues,they were divided into negative group and positive group. Pemetrexed combined with cisplatin and Bevaci-zumab was given. The clinical efficacy of the two groups was compared,and vascular endothelial growth factor(VEGF)andBcl-2 in lung tissues were measured. Multivariate analysis was used to analyze the prognosis of patients.ResultsThe effec-tive rate of clinical treatment in positive group was significantly lower than that in negative group(P<0.01). There was nosignificant difference between the positive group and the negative group(P>0.05),but the serum CECs level was significant-ly higher in the positive group than in the negative group(P<0.05). COX regression analysis showed that smoking,Beclin-1 positive,high expression of CECs and CEPCs were independent prognostic factors.ConclusionHigh expression of Beclin-1 protein may affect the sensitivity of anti-angiogenic factor therapy in patients with metastatic lung cancer and worsen theircondition.
作者
刘劲松
於海军
李丽萍
刘俊
李小菊
LIU Jin⁃song;YU Hai⁃jun;LI Li⁃ping;LIU Jun;LI Xiao⁃ju(Department of Oncology,Xiantao First People's Hospital,Xiantao,Hubei Province 433000,China)
出处
《解剖学研究》
CAS
2019年第6期509-512,共4页
Anatomy Research
基金
湖北省卫生计生科研项目(WJ2018H184)
